06-562
Anti-erbB-2/HER-2 Antibody
Upstate®, from rabbit
Synonym(s):
CD340 antigen, CD340 antigen, NEU proto-oncogene, Tyrosine kinase-type cell surface receptor HER2, c-erb B2/neu protein, c-erb B2/neu protein, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
monkey, human, mouse
species reactivity (predicted by homology)
rat
manufacturer/tradename
Upstate®
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... ERBB2(2064)
mouse ... Erbb2(13866)
rat ... Erbb2(24337)
rhesus monkey ... Erbb2(697573)
General description
The ErbB-2 proto-oncogene, also called Neu, EGFR-2 or HER-2, is a member of the transmembrane receptor tyrosine kinase family, which also includes EGF receptor and EGFR-3 (HER-3 or ErbB-3). Although, ErbB-2 does not have any known high-affinity ligands, its kinase activity can be activated without ligand by either overexpression or heteroassociation with other members of the ErbB family. Amplification of the ErbB-2 gene and overexpression of its product has been detected in almost 40% of primary human breast tumors, which correlates with poor prognosis in node positive breast cancer. ErbB-2 overexpression is also observed in ovarian, gastric, salivary and non-small cell lung carcinomas. Because of this, ErbB-2 is one of the major drug targets for breast cancer and other cancer treatments.
Specificity
Recognizes c-erbB-2 (185 kDa), but not c-erbB-1(EGF-R), c-erbB-3 or c-erbB-4.
Immunogen
A KLH-linked peptide (AENPEYLGLDVPV) corresponding to aa 1243-1255 from the human c-erbB-2/HER-2/neu oncoprotein.
Application
Anti-erbB-2/HER-2 Antibody is an antibody against erbB-2/HER-2 for use in IH, IP & WB.
Immunoprecipitation:
4 μg of a previous lot immunoprecipitated erbB-2/HER-2 from 600 μg MCF-7 RIPA lysate, and previously in A431, LNCaP, and c-erbB-2 transfected 3T3/NIH RIPA lysate.
Immunohistochemistry:
A previous lot of antibody has been reported by an independent laboratory, to detect erbB-2/HER-2 in frozen and formalin/paraffin sections of rat breast.
4 μg of a previous lot immunoprecipitated erbB-2/HER-2 from 600 μg MCF-7 RIPA lysate, and previously in A431, LNCaP, and c-erbB-2 transfected 3T3/NIH RIPA lysate.
Immunohistochemistry:
A previous lot of antibody has been reported by an independent laboratory, to detect erbB-2/HER-2 in frozen and formalin/paraffin sections of rat breast.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
Quality
Routinely evaluated by Western Blot on HEK293 lysates.
Western Blot Analysis:
1:500 dilution of this lot detected Her-2 on 10 μg of HEK293 lysates.
Western Blot Analysis:
1:500 dilution of this lot detected Her-2 on 10 μg of HEK293 lysates.
Target description
185 kDa
Linkage
Replaces: 04-1127
Physical form
Format: Purified
Protein A purified
Purified rabbit polyclonal IgG in buffer containing 10 mM PBS, pH 7.4, 0.2% BSA and 0.09% sodium azide. Frozen solution.
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
A431 cells, HEK293, Jurkat, MCF7 cell lysate.
A431 cells, HEK293, Jurkat, MCF7 cell lysate.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Increased expression of epidermal growth factor receptor induces sequestration of extracellular signal-related kinases and selective attenuation of specific epidermal growth factor-mediated signal transduction pathways.
Amyn A Habib, Soo Jin Chun, Benjamin G Neel, Timothy Vartanian
Molecular Cancer Research null
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.
Paik, S, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8, 103-112 (1990)
Introducing the cancer microenvironment section of Journal of Translational Medicine.
Fernando Vidal-Vanaclocha,Isaac P Witz
Journal of Translational Medicine null
Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers.
Vernimmen, D; Gueders, M; Pisvin, S; Delvenne, P; Winkler, R
British Journal of Cancer null
Valentina Pirazzoli et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(2), 426-435 (2015-09-06)
The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost all patients who respond develop acquired resistance on average approximately 1 year after starting therapy. Resistance is commonly due to
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service